Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Different Experiences in Chronic Migraine Etiology, Treatment and Comorbidities of Hawaii’s Ethnic Groups
Headache
P14 - Poster Session 14 (11:45 AM-12:45 PM)
2-006
Chronic migraine (CM) is a debilitating condition with negative repercussions on the socioeconomic status of patients; compounded by under-diagnosis and treatment in minority populations. Identifying treatment and comorbidity characteristics of CM patients in Hawaii will guide treatment of migraines.
To determine racial disparities in CM treatment and comorbidities of patients in Hawaii, a state characterized by its a majority-minority patient population. We hypothesize that minority populations are under-treated. 
We performed a retrospective chart review on patients diagnosed with CM at a headache and facial pain center in Honolulu, Hawaii. 743 patients with a clinic visit from January 27, 2022 to April 27, 2022 were retrieved from eClinicalWorks. Patients without sufficient data were excluded, yielding 298 patients fulfilling inclusion criteria of a) ICD-10 code diagnosis of CM b) lack of secondary migraine etiology and c) fulfilling IHCD-3 standards of CM. Socioeconomic demographic variables were collected including self-reported race, age, obesity, number of medications and public/private health insurance. Patient treatment modalities were recorded: botulinum toxin (BoNT), pharmacologic treatment, monoclonal antibodies, and physical therapy.
Native Hawaiian/Pacific Islander (NHPI) patients reported the highest prevalence of obesity (60.9%) at  >30% compared to other race groups (p<0.001). History of diabetes was low across all race groups (7.7%). However, NHPI patients had a higher history of diabetes (14.5%) (p= 0.004), hypertension (37.7%), >13% higher than other race groups (p= 0.01). Significantly more white patients received BoNT as therapy (73.9%), >25% compared to other race groups (p= 0.02). Public insurance was significantly more common in NHPI patients (59.4%) followed by other minorities (57.1%), with a 9-11% difference compared to other race groups. (p=0.02)
Our findings suggest barriers to BoNT treatment in minority patients. Comorbidities in NHPI patients, such as obesity, diabetes and hypertension, differ from other ethnic groups.
Authors/Disclosures
Enrique Carrazana
PRESENTER
Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Neurelis, Alexza, Zogenix. Enrique Carrazana has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Hawaii-Biotech, CND Life Sciences. Enrique Carrazana has stock in Neurelis, Marinus, .
Michelle Xiaoyi Lu Miss Lu has nothing to disclose.
Kacey L. Yamane Ms. Yamane has nothing to disclose.
Dane Keahi Mr. Keahi has nothing to disclose.
Michael Tong Mr. Tong has nothing to disclose.
Connor Goo Mr. Goo has nothing to disclose.
Devashri Prabhudesai, Other The institution of an immediate family member of Ms. Prabhudesai has received research support from National Eye Institute. An immediate family member of Ms. Prabhudesai has received intellectual property interests from a discovery or technology relating to health care.
John J. Chen, PhD The institution of Dr. Chen has received research support from NIH.
Vimala Sravanthi Vajjala, MD (Hawaii Pacific Neuroscience) Dr. Vajjala has nothing to disclose.
Jason Viereck, MD, PhD (Adventist Health Castle Hospital) Dr. Viereck has nothing to disclose.
Kore K. Liow, MD, FACP (University of Hawaii, John Burns School of Medicine) The institution of Dr. Liow has received research support from UCB. The institution of Dr. Liow has received research support from Livanova. The institution of Dr. Liow has received research support from Biogen. The institution of Dr. Liow has received research support from Novartis. The institution of Dr. Liow has received research support from Eisai. The institution of Dr. Liow has received research support from Engage Therapeutics. The institution of Dr. Liow has received research support from SK Lifescience. The institution of Dr. Liow has received research support from Cerevel. The institution of Dr. Liow has received research support from Xenon. The institution of Dr. Liow has received research support from NeuroDerm. The institution of Dr. Liow has received research support from Avanir. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Acadia. The institution of Dr. Liow has received research support from Prothena. The institution of Dr. Liow has received research support from SAGE. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Cyclerion.